drugset / Trial / NCT00043303

Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

NCT00043303

Phase 2 Completed 502 enrolled InterMune
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with chronic hepatitis C infections. IFN-g 1b is not currently approved for the treatment of liver fibrosis.

Timeline

Start
2001-09
Primary completion
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon gamma-1b Protein / enzyme biologic 100 ug Subcutaneous
Subject Interferon gamma-1b Protein / enzyme biologic 200 ug Subcutaneous